You also can follow Dr Proton on :
👉 "54 GyRBE to a limited volume effective for disseminated spinal MPE, sparing children the toxicity of full craniospinal irradiation.
#protontherapy improves the therapeutic ratio, resulting in minimal side effects and high rates of disease control"
https://pubmed.ncbi.nlm.nih.gov/33226179/
Very true, much more action and resources to be mobilised to address the chronic lack of #radiotherapy in #Africa - a life-saving treatment for invasive #CervicalCancer & an integral part of @WHO’s Global Elimination Strategy. @iaeaorg @rafaelmgrossi @marykge @DrNonoSimelela https://twitter.com/OphiraG/status/1328763036908318722
@drkevinknopf @IARCWHO @WHO Indeed and there are many countries particularly in sub-Saharan Africa who have zero radiotherapy machines! Lots being done now – but not nearly enough. All hands on deck! #CervicalCancer @IARCWHO @WHO @DrNonoSimelela @NCIGlobalHealth
FEBRUARY
26
2020
FEBRUARY
26
2020
February, 26th, 2020 – Atlanta, Georgia U.S.A.
In February, SAH has conducted patient follow-up clinics in Bahrain for patients previously treated in the US, and held a guest lecture about Proton Therapy at King Hamad University Hospital.
In 2011, SAH has signed an agreement with the Ministry of Health of the Kingdom of Bahrain to take patient who qualify for Proton Therapy to partner centers in the US for Cancer Treatment. For each patient, once the treatment plan has been discussed and validated by the local oncologists, by the Overseas Treatment Committee, and by the SAH Care Team, SAH Care organizes the travel and treatment at one partnering facilities. Twice a year, the SAH physicians come in the Middle-East & Africa region to see the patients they have treated with Proton Therapy in the US.
Dr Atman Pai has conducted last week those patient follow-up clinics in Bahrain.
Bahraini pediatric patients previously treated by SAH Care in the US have been seen at Salmaniya Medical Complex. Dr khulood and her team have outstandingly coordinated the consultations with our young patients.
Adult patients have been seen at King Hamad University Hospital with the remarkable Dr Hanadi Malik, Radiation Oncologist at KHUH.
SAH also held a lecture about Proton Therapy at King Hamad University Hospital presenting a practical approach to Proton Therapy.
Proton therapy has gained acceptance throughout the world, but it remains difficult to define which patients benefit the most of Proton Therapy.
Utilizing proton therapy is quickly becoming the best practice for pediatric radiation oncology services. Proton Therapy is a form a radiation therapy which aggressively treats the tumor while substantially reducing side effects that could impact the child’s development and quality of life. This advanced cancer therapy has been proven to protect vital organs, important tissues, nerves, and glands during treatment, while also decreasing the estimated risk of secondary malignancies.
Proton Therapy is also very beneficial for adult patients with cancer that occurs near vital organs. It can be precisely and narrowly targeted specifically on cancerous tumors and tissues, applying intense amounts of radiation only to the affected area. This advanced therapy is most commonly used for localized cancer and tumors that have not spread, or metastasized, to other distant parts of the body.
Proton Therapy is ideally suited as well to minimize toxicity to previously irradiated organs. It offers dosimetric advantages for normal tissue sparing and it provides effective tumor control with acceptable acute and late toxicity profiles because of the decreased dose to the surrounding normal, albeit previously irradiated, tissue. Proton beam therapy can be a safe and effective curative reirradiation strategy, with acceptable rates of toxicity and durable disease control.
In 2020, we’ll keep advocating, explaining the benefits of Proton Therapy, and fighting to make sure that the patients who need the most this treatment can get it on time.
SEPTEMBER
10
2019
SEPTEMBER
10
2019
September 10th, 2019 – Atlanta, Georgia U.S.A.
SAH and Neutron Therapeutics Inc. enter into agreementto develop Boron Neutron Capture Therapy
SAH Global and neutron Therapeutics Inc (NTI) have entered into agreement to develop Boron Neutron Capture Therapy (BNCT).
BNCT is a powerful alternative to traditional radiotherapy and proton therapy, with the ability to deliver targeted radiation to cancer cells while sparing surrounding healthy tissue.
In BNCT treatment, a boron carrier compound injected into the blood stream is selectively absorbed by tumor cells. The tumor is irradiated with a therapeutic neutron beam. The neutron beam reacts with the boron, while safely passing through surrounding tissue. The boron reaction produces highly excited alpha particles of very short path lengths (5–9 µm) that destroy tumor cells from the inside with minimal effect on immediately surrounding tissue. BNCT has successfully been used to treat cancer patients in cases where other treatment options have been exhausted. Typical BNCT therapies utilize two patient treatments vs. dozens for traditional radiotherapy, reducing stress on patients while enhancing treatment center efficiency and patient throughput.
NTI’s unique and patented neutron source replaces the nuclear reactor in traditional BNCT research platforms. Engineered from the ground up for high reliability and ease of maintenance, NTI’s platform can enable the widespread adoption of BNCT.
SAH is committed to the development and introduction of state-of-the-art cancer treatment technology in the Middle-East, Africa, Latin America, and Asia.
Through this agreement, SAH and NTI will collaborate to secure FDA and CE marks, and to introduce BNCT as a treatment for cancer patients worldwide.
About SAH Global
Strategic Alliance Holdings Global, LLC (“SAH Global”), is a holding company founded in 2005 to establish highly specialized projects in areas such as healthcare. SAH Global has actively pioneered the effort to bring vital cancer treatment solutions to the Middle East. SAH Global believes in building a strong sustainable society, and as such, will leverage the success of its global ventures to make long-term contributions to the community, promote the growth of their employees, and help create a greener environment.
About SAH Care
SAH Care was established to ensure that patients from across the world can have access to the best treatments available. We work tirelessly with local physicians and a global network of leading healthcare providers to bring excellent quality cancer care to our patients. Our team, partners, and supporters share a commitment to improve the delivery of high-quality, patient-centric cancer care.
Through travel medicine, we have found a way to provide access to advanced cancer care for those who live in areas where proton therapy centers are yet to be built. We believe that patients deserve to receive the most advanced cancer treatment in the world today despite geographic boundaries and limitations. The SAH Care team provides this compassionate, comprehensive care to patients wherever they live.
About NTI
Neutron Therapeutics is a Boston-area medical equipment company founded in 2015 by New Zealander, Bill Buckley. The mission of NTI is to provide innovative technology solutions that will enable BNCT to realize its maximum potential in the treatment of difficult cancers.
The Neutron Therapeutics neutron source is not approved for commercial or clinical use by the FDA or EMA or other regulatory body.
AUGUST
9
2019
AUGUST
9
2019
August 9th, 2019 – Atlanta, Georgia U.S.A.
Feroz AGAD, Founder, Chairman and Chief Executive of SAH Global and SAH Care appointed to the Advisory Board of Neutron Therapeutics Inc.
Neutron Therapeutics Inc. (NTI) is a Medical Equipment Company founded in 2005 to bring Boron Neutron Capture Therapy (BNCT) out of the realm of medical research and transform it into a widely available first-line cancer therapy.
NTI has developed an accelerator-based, in-hospital neutron source composed of a 2.6 MeV electrostatic proton accelerator and a rotating, solid lithium target for generating neutrons. NTI will provide this neutron source as part of a comprehensive therapeutic treatment suite, that will combine all of the necessary components for BNCT treatment into a user-friendly package.
BNCT is a unique type of radiation therapy that enables targeting of cancer at the cellular level and treating cancer with a non-invasive two-step process. First, patients are injected with a tumor-seeking drug containing a non-radioactive isotope (boron-10) with a high neutron capture cross-section. In the second step, the patient is exposed to a beam of low energy neutrons, many of which are absorbed by the boron-10. The absorption initiates a reaction that emits short-range, high-energy charged particles. Which systematically destroy the tumor cells while imparting relatively little damage to adjacent areas of healthy tissue.
Feroz AGAD is an accomplished executive, investor and entrepreneur with over 15 years experience of managing multimillion-dollar corporations in industries including healthcare, real estate, communications, tourism and information technology. By capitalizing on his business acumen, technical expertise, interpersonal skills and strategic mindset, Mr. Agad has been instrumental in penetrating new markets and achieving significant sales growth for the companies he has previously founded and managed. Mr. Agad presently sits on the board of directors at four companies and sits on three advisory boards, a committee for a non-profit humanitarian organization and a committee on education.
He established SAH in 2004 with the vision of using the company as a catalyst to bring cutting edge Healthcare technology to the developing world. SAH Global is currently focused on establishing a global network of Proton Therapy Cancer Centers, while SAH Care is the medical treatment abroad division which currently brings cancer patients from around the world to SAH’s network of Cancer Centers for treatment in the USA.
In his overall reach in the fight against cancer, Feroz AGAD has particularly impacted the Industry of Proton Therapy and has demonstrated an exceptional spirit of Innovation to ensure patients from across the world have access to best treatment available. Feroz AGAD defines the future readiness of the Oncology organizations to not only meet the market demand, but to provide compassionate and comprehensive care to patients wherever they live.
With this appointment, NTI will use the experience of Feroz AGAD and of the SAH teams to develop its business, to get the regulatory approvals such as FDA and CE marks, and to conduct the necessary clinical studies to make BNCT available to more of the patients who could benefit from this exciting technique.
About SAH Global
Strategic Alliance Holdings Global, LLC (“SAH Global”), is a holding company founded in 2005 to establish highly specialized projects in areas such as healthcare. SAH Global has actively pioneered the effort to bring vital cancer treatment solutions to the Middle East. SAH Global believes in building a strong sustainable society, and as such, will leverage the success of its global ventures to make long-term contributions to the community, promote the growth of their employees, and help create a greener environment.
Read more on https://www.sahglobal.com
About SAH Care
SAH Care was established to ensure that patients from across the world can have access to the best treatments available. We work tirelessly with local physicians and a global network of leading healthcare providers to bring excellent quality cancer care to our patients. Our team, partners, and supporters share a commitment to improve the delivery of high-quality, patient-centric cancer care.
Through travel medicine, we have found a way to provide access to advanced cancer care for those who live in areas where proton therapy centers are yet to be built. We believe that patients deserve to receive the most advanced cancer treatment in the world today despite geographic boundaries and limitations. The SAH Care team provides this compassionate, comprehensive care to patients wherever they live.
Read more on https://www.sahcare.com
About NTI
Neutron Therapeutics is a Boston-area medical equipment company founded in 2015 by New Zealander, Bill Buckley. The mission of NTI is to provide innovative technology solutions that will enable BNCT to realize its maximum potential in the treatment of difficult cancers.
The Neutron Therapeutics neutron source is not approved for commercial or clinical use by the FDA or EMA or other regulatory body.
Read more on https://www.neutrontherapeutics.com
NOVEMBER
13 & 14
2018
NOVEMBER
13 & 14
2018
SMART HEALTH CONFERENCE
Don’t miss the Keynote Speech by Mr Feroz AGAD – Founder, Chairman, and Chief Executive Officer of SAH Global & SAH Care – on November 13th in Dubai on the role of Proton Therapy in the Global Cancer Care System.
NOVEMBER
08
2018
NOVEMBER
08
2018
Lacort Medical and SAH Global Bringing Comprehensive Oncology Treatment, Training and Education to Latin America.
Bristol – November 7, 2018. We are pleased to announce a partnership between SAH Global (“SAH”) and Lacort Medical (“Lacort”), to bring Comprehensive Oncology, including Proton Beam Cancer Therapy (“PBT”) and other medical treatments, training & education to Latin America (“LatAm”). According to the World Health Organization, cancer is the second leading cause of death in Latin America, behind cardiovascular diseases.
NOVEMBER
06
2018
NOVEMBER
06
2018
Proton therapy for pediatric brain tumors has favorable cognitive outcomes
“Based on radiation dose profiles, we have always anticipated that children with brain tumors would derive cognitive benefits of proton therapy relative to conventional X-ray therapy,” commented senior author Vinai Gondi, MD, director of Research & Education at the Northwestern Medicine Chicago Proton Center. “This study provides our first and most compelling clinical evidence of the importance of using proton therapy to spare as much normal brain tissue as possible.”
OCTOBER
25
2018
OCTOBER
25
2018
Hampton University Proton Therapy Institute is hosting another Breast Cancer Awareness Month event on October 25th at 6:30 p.m.
During the event, you can hear stories from former patients, learn more about proton therapy, and tour the facility. This complimentary seminar, led by a HUPTI radiation oncologist, is open to prospective patients or anyone wanting to learn more about proton therapy.
OCTOBER
13
2018
OCTOBER
13
2018
SAH honored to have received His Excellency Sheikh Nahyan bin Mubarak Al Nahyan during the UAE Cancer Congress
The 10th UAE Cancer Congress has been a great event. SAH has been honored to have received His Excellency Sheikh Nahyan bin Mubarak Al Nahyan, Cabinet Minister, Minister of Tolerance in the UAE and President of the UAE Genetics Association, and Dr. ShaheenahDawood, Head of MedicalOncology and Head of the BreastCancer Program at Dubai Hospital in the United Arab Emirates.
OCTOBER
11 – 13
2018
OCTOBER
11 – 13
2018
Come meet with SAH INTEGO during the UAE Cancer Congress.
Meet our team based in Dubai Healthcare City, your NEIGHBORHOOD HEALTHCARE PARTNER, to discussProton Therapy and Advanced Cancer Treatments.
Email : [email protected]
Tel: +971 (0)4 455 1004
OCT
12
2018
OCT
12
2018
Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
Many patients are increasingly aware of the multitude of options and technologies available for the diagnosis and treatment of prostate cancer, thanks to the ease of finding information on the internet. However, the amount of information that is available is overwhelming and there is a need for objective, expert guidance to determine which paradigm best suits each patient, depending upon their individual circumstances. In many cases, insurance coverage dictates what the patient is able to consider, irrespective of the patient’s preference.
Too often, when men consult a practitioner offering surgery, they are encouraged to have surgical intervention without being counseled about the potential for significant quality of life issues that may ensue such as impotence and urinary and bowel incontinence. The patient is often told that a prostatectomy is the “Gold Standard” and they don’t hear about other options. Sometimes, the patients just want to “get it out” and don’t realize that there’s a significant potential that there could be a recurrence within several years.
Conversely, patients who confer with a radiation oncologist may not be made aware of the possibility of rectal toxicity. Practitioners who offer only photon IMRT may not make the patient aware of proton therapy or brachytherapy, or the possibility of combining these modalities.
OCT
11
2018
OCT
11
2018
Hampton University Proton Therapy Institute is hosting a Breast Cancer Awareness Month event on October 11th at 6:30 p.m.
The Hampton University Proton Therapy Institute (HUPTI) will devote a special “Live your Life” seminar to Breast Cancer Awareness Month on Thursday, October 11th at 6:30 p.m. at their institute.
During the event, you can hear stories from former patients, learn more about proton therapy, and tour the facility. This complimentary seminar, led by a HUPTI radiation oncologist, is open to prospective patients or anyone wanting to learn more about proton therapy.
FDA-approved proton therapy has been used to treat cancer since 1990. The treatment differs from other radiation therapies by delivering a precise dose of energy to the targeted area. When compared to other cancer treatment options, proton therapy often results in fewer side effects and less damage to the surrounding healthy breast tissue and organs, while also limiting cosmetic damage, skin necrosis, and rib fracture.
OCT
05
2018
OCT
05
2018
Bone sarcomas: ESMO–PaedCan–EURACAN: Clinical Practice Guidelines for diagnosis, treatment and follow-up
Particle therapy (high-dose protons or carbon ions) provide a better local control, survival and allow lower doses to be given to normal tissues and should, therefore, be considered the treatment of choice in some cases.
SEPT
29
2018
SEPT
29
2018
Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot
(…)Proton therapy offers an alternative method of RT for patients for whom photon-based EBRT is suboptimal. Although IMRT is a highly conformal radiation technique, low to intermediate doses to surrounding nontarget organs is unavoidable. In contrast to photon-based EBRT, proton therapy deposits most of the radiation energy within the target area rather than the surrounding healthy tissues outside the target volume. Proton therapy is preferable for patients with recurrent tumors in previously irradiated areas and tumors near radiation-sensitive structures because of its physical properties, which allow for a sharp drop-off in dose in the surrounding healthy tissues, including radiosensitive OARs
(…)proton palliative RT can benefit those who cannot receive photon-based palliative RT because of tumor location or prior local radiation, and it provides benefit to patients who have had previous radiation through decreased cumulative dose to sensitive surrounding tissue . The proton quad shot regimen offers an alternative option for symptom palliation for patients not amenable to palliative photon RT.
(…)proton therapy offers the unique advantage of delivering a negligible radiation dose to healthy tissues behind the target volume.
SEPTEMBER
24 – 25
2018
SEPTEMBER
24 – 25
2018
Importance of working together
Don’t miss the Keynote Speech By Feroz Agad, Founder & Chairman of SAH Global – Proton Therapy Cancer Treatment, USA at 3rd World Conference on Breast and Cervical Cancer the one in Abu Dhabi, UAE.
To join mail us at Email: [email protected] & [email protected]
SEPT
09
2018
SEPT
09
2018
Proton therapy – a reality in Norway from 2023
It has finally been decided to establish proton therapy as a national treatment option in Norway, and there will be centres in Oslo and Bergen from 2023. The majority of children and young adults who are to receive curative radiation therapy should be treated with proton therapy.
Particle therapy is used as a collective term for radiation therapy using heavy ions. In general, regular radiation therapy in Norway currently consists of photon therapy (high-voltage x-ray radiotherapy). The ion that is most commonly used in particle therapy is the proton, and of around 175 000 patients treated worldwide at the end of 2016, 150 000 were treated with proton therapy (1). The other ion in use today is the carbon ion, and globally a little more than 20 000 patients have received carbon ion therapy.
Although heavy ions have been used to a limited extent for therapeutic purposes since the 1950s, only in the last 20 years has this really become an intrinsic part of the cancer treatment programme. The number of patients treated has increased by a factor of almost ten in this period. The main advantage of proton and carbon ions in radiation therapy, compared with photons, is that the physical properties of the ions allow for a better radiation dose distribution for most tumours, so that they cause damage to the tumour rather than to normal tissue. This does not necessarily result in a higher cure rate, but in the adverse effects of radiation therapy (late effects) being less pronounced than is the case for current, regular photon therapy. This results in considerably improved quality of life for patients who live for many years after cancer treatment. A number of adverse effects may manifest themselves up to 15–20 years after radiation therapy, and therefore young patients, patients with a long life expectancy, and patient groups with major adverse radiation-related effects may derive most benefit from proton therapy.
The benefits of proton therapy
Throughout the years of assessments in Norway, a great deal of discussion has taken place regarding the extent of the need for proton therapy, as well as the ethical aspects of the treatment (6–9).
The prevailing opinion based on our current knowledge is that the majority of children who are to receive radiation therapy with curative intent should be given proton therapy (6). It is known that reduced radiation to normal tissue reduces the risk of late effects and secondary cancer, and it is therefore highly probable that proton therapy is particularly advantageous for children (8). However, no randomised trials have been undertaken on children, as this is viewed as ethically problematic.
For adults the picture is more complex. Generally young adults with tumours in or near the central nervous system should be prioritised for the same reason as children. Chordomas, chondrosarcomas and ocular tumours that need external radiation therapy are considered to be relatively well-established indications for particle therapy (9, 10). In the case of sinonasal cancer, a number of studies have been undertaken that compared patient cohorts that have undergone particle and photon therapy. These studies have been included in a meta-analysis which concludes that particle therapy is beneficial for this diagnosis (11).
AUG
27
2018
AUG
27
2018
Radiation Therapy Affects Event Recall for Children With Brain Tumors
“The study identifies an area of cognition that is inadvertently impacted by standard treatment methods, which has real consequences for the quality of life of the survivors. The physicians’ ultimate goal is to allow their patients to survive and to live as well as possible,” Sekeres said. “Although these treatments are often crucial in the effective management of the cancer, if the physicians and the family know there are these unintended side effects, that may be an additional factor to consider when exploring the treatment options.”
AUG
20
2018
AUG
20
2018
What is the acceptable radiation dosage to the hearts and lungs for a breast cancer patient in her 20s undergoing radiation therapy?
A small amount of lung tissue is irradiated when treating the breast, but the proportion of the total lung capacity is inconsequential – 2–3% at most.
The heart is another story. There is no radiation dose considered completely safe for the heart.
With modern treatment techniques, most Radiation Oncologists try to keep the mean dose below 2 Gy*. But 20 year F/U data on patients treated for left sided breast cancer shows a 7% increase in the likelihood of having a significant cardiac event (myocardial infarction, the development of cardiomyopathy, symptomatic coronary vascular disease, etc.) for every Gy mean heart dose given.
We can usually limit the heart dose to < 1–2 Gy for left sided breast cancer patients with standard x-ray radiation therapy techniques. Sometimes that includes having the patient hold their breath while the machine is treating, to bring the chest wall away from the heart. These techniques usually work unless we have to treat the lymph nodes, for more advanced cancers – especially the internal mammary lymph nodes, which lie immediately in front of the heart.
The only way to accomplish that is with Proton Beam Irradiation – which allows us to treat the breast and all the draining lymph nodes with essentially ZERO dose to the heart.
AUG
17
2018
AUG
17
2018
Hampton University Proton Therapy Institute is sponsoring Prostate Cancer Awareness Night on August 22 at the Norfolk Tides baseball game
Proton therapy, one treatment option for prostate cancer, delivers a radiation dose directly to the tumor, sparing healthy, normal tissue. The process is non-invasive and doesn’t require a hospital stay.
“When you don’t irradiate sensitive surrounding tissues, you drive down the side effects,” says Dr. Christopher Sinesi, medical director of the Hampton University Proton Therapy Institute, which opened eight years ago and has treated more than 2,500 patients. “The prospect of higher cure rates with fewer side effects – that’s what all the excitement is about.”
AUG
05
2018
AUG
05
2018
Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives
AUG
02
2018
AUG
02
2018
Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy
JULY
31
2018
JULY
31
2018
What is Cancer Radiotherapy and How Does it Work?
www.technologynetworks.com Cancer Research UK
JULY
20
2018
JULY
20
2018
Alliance for Proton Therapy Access emphasizes power of protons during National Sarcoma Awareness Month
In recognition of National Sarcoma Awareness Month in July, the Alliance for Proton Therapy Access is underscoring the importance of patient access to proton radiation therapy, a clinically-effective treatment for patients diagnosed with sarcoma cancers.
Proton therapy is an FDA-cleared treatment that allows physicians to precisely control and conform the bulk of its cancer-fighting proton energy field on the cancerous cells, thereby minimizing extraneous radiation dose to healthy tissues, preserving organ function, and potentially reducing harmful side effects. This makes the treatment ideal for some sarcoma cancer patients, as sarcoma tumors are often located near sensitive tissues. One study shows that high-dose proton therapy controls more than half of spinal chordomas and chondrosarcomas and compares favorably with historical traditional (photon) radiation data.
“The successful treatment of my recurrent sarcoma cancer illustrates the power of proton therapy. I am living proof that proton therapy is a legitimate, safe, and effective cancer treatment,” said Cindy Lee, a cancer survivor and advocate. “I encourage others to join me in advocating for policies that ensure timely access to treatment for cancer patients in need of proton therapy.”
JULY
09
2018
JULY
09
2018
Hadron Therapy Ready for Takeoff
JULY
02
2018
JULY
02
2018
The Korean National Cancer Center celebrates 11 years of proton therapy saving patients
The National Cancer Center said it has reaped meaningful results in proton therapy to treat cancer during the past 11 years, after introducing it to Korea for the first time in 2007.
(…)
Proton therapy good in liver, pancreatic, eye, lung cancer
NCC held a press conference at Goyang Aram Nuri in Goyang, Gyeonggi Province, on Friday to promote the proton therapy’s clinical effectiveness. The hospital also held an international symposium on “Clinical Evidence in Particle Therapy & Current Status of Particle Therapy in Asia-Oceania” at the NCC’s cancer prevention and examination center in Goyang on Friday and Saturday.
The proton therapy was effective particularly for radiation-treated but recurrent cancers such as spinal cord chordoma and head and neck cancer, NCC said.
“The proton therapy showed an excellent therapeutic effect in liver cancer and pancreatic carcinoma with low survival rate,” said Kim Tae-hyeon, head of the NCC’s proton therapy center. “In patients with liver cancer, patients who could not have surgery due to poor liver function with smaller than 8-centimeter tumor showed more than 90 percent of complete remission rate within one year. Their three-year survival rate was 74 percent.”
Kim went on to say that a patient with locally advanced hepatocellular carcinoma who accompanied tumor thrombosis with a poor prognosis had a remarkable treatment result with the two-year survival rate exceeding 50 percent, in combination with other therapies.
“In a pancreatic cancer patient who could not undergo surgery, the proton therapy showed a similar treatment result with those who had surgical resections,” Kim added.
The proton treatment is also effective on eye cancer, as most other surgeries require the removal of the eyeball. The proton treatment precisely targets cancer cells only, preserving the eyeball and the sight.
“In choroidal melanoma, the most common type of eye cancer, patients had a 95 percent local tumor control rate and a 100 percent three-year survival rate after the proton therapy,” said Moon Seong-ho, a specialist at the NCC’s proton therapy center.
Another physician Seo Yang-kwon at the center said first-stage lung cancer patients who could not have surgery had an 85.4 percent three-year local tumor control rate after the proton therapy. Those whose tumors were smaller than 3 centimeters had a 94 percent rate.
“Patients in stage-1 esophageal cancer had a 90 percent local tumor control after the proton treatment, too,” he added.
JUNE
08
2018
JUNE
08
2018
Tom Garrett - Tonsillar Cancer : "Proton not only saved my life but who I am"
My name is Tom. I’m the lead singer for the international recording group The Classics IV and this is my story. Just over two years ago March 30, 2016, I was diagnosed with Tonsillar Cancer. Initially I was told that the only course of treatment was surgery to remove the tumors followed by chemo therapy, that I might lose my ability to eat without a feeding tube, might lose my ability to speak properly and of course might no longer be able to perform. I was faced with a multitude of decisions that could change my life as I had known it since I was 15 years old.
We scheduled the surgery and headed home. After returning home it took a couple of days to try and come to terms with the future. I sat down at my computer and googled “Non-Surgical Treatment for Tonsillar Cancer” the first item that came up was proton treatment. I had never heard of Proton Treatment let alone that I might ever need it. I read everything I could find about it, what really excited me was that it could provide treatment without damaging the surrounding tissue. That google search started the journey of a lifetime.
My final treatment was on July 23, 2016, six weeks and three days later I was on stage in Las Vegas in front of over 3,500 people and I sang! Today I sit here cancer free! In the world of cancer there are many different forms of treatment for various forms of the disease and proton may not work for everyone. In fact I was told by one doctor at a highly regarded hospital that proton was the wrong treatment plan for me. That opinion turned out to be WRONG.
The moral of this now not so short story: it’s your life get a second opinion before you choose your path to recovery, not every doctor knows everything. Proton not only saved my life but who I am. So, I’m still performing thanks to an amazing caring staff, from the front desk to the nurses, technicians and doctors, especially Dr. John Han-Chih Chang. People really do make the difference.
http://www.rtanswers.org/TomGarrett/
JUNE
04
2018
JUNE
04
2018
Irradiating chest lymph nodes in patients with early stage breast cancer improves survival without increasing side effects
(…) trial has given solid evidence of the benefits of radiation treatment of the Internal Mammary – Medial Supraclavicular lymph nodes (…)
MAY
22
2018
MAY
22
2018
New therapy for pediatric brain tumors could reduce long-term cognitive issues
Children with brain tumors who receive conventional photon radiation therapy are at risk for experiencing cognitive changes after treatment. That’s because the radiation not only treats the tumor but it can also impact the healthy tissue surrounding it.
With proton beam radiation therapy, research suggests that these cognitive changes will be less severe. This technology allows radiation oncologists to more precisely apply radiation dose to the tumor so the child’s healthy brain tissue is not exposed to as much radiation and can continue growing and developing.
MAY
16
2018
MAY
16
2018
‘Proton therapy killed tumor in 70% of liver cancer patients’
MAY
03
2018
MAY
03
2018
Alliance for Proton Therapy Access emphasizes need for timely treatment during Brain Tumor Awareness Month
MAY
01
2018
MAY
01
2018
Inaugural NCCN Guidelines Designated for Uveal Melanoma
APR
26
2018
APR
26
2018
Dosimetric comparison of five different techniques for craniospinal irradiation
APR
20
2018
APR
20
2018
Proton Beam Therapy Alone for Intermediate- or High-Risk Prostate Cancer: An Institutional Prospective Cohort Study.
JAN
31
2018
JAN
31
2018
SAH Global signs an agreement with the Group Florence Nightingale Hospital
We are proud to announce the signature of a collaboration agreement between SAH Global and the Group Florence Nightingale Hospital (GFNH) in order to provide end to end service in the field of oncology.
JAN
30
2018
JAN
30
2018
SAH Global signs an agreement with Intego Health in Dubai, UAE
SAH Global signed a JV Agreement with the Intego Health team. Through our newly formed SAH-Intego Health JV we plan on providing training and education across many vertices in Healthcare as well as utilize our collective network to distribute our products and services.
JAN
29
2018
JAN
29
2018
DEC
05
2017
DEC
05
2017
Proton beam therapy (PBT) in children and young adults with nonhematologic malignancies of the head and neck appeared to be safe and delivered local control rates similar to those seen historically.
NOV
14
2017
NOV
14
2017
OCT
29
2017
OCT
29
2017
A single mother from Sydney reveals how ‘Facebook saved her life’ after cancer. In November 2016 she was told she had a rare brain cancer and would die. She found out about proton therapy on social media and went to America for it. The therapy was successful, she has a 95 percent chance of surviving 15 years. The therapy could be available in Sydney as soon as 2020, campaigners say.
OCT
27
2017
OCT
27
2017
Proton therapy may ensure higher survival rates and a decline in complications among prostate cancer patients compared to intensity-modulated radiation therapy (IMRT).
OCT
27
2017
OCT
27
2017
OCT
26
2017
OCT
26
2017
OCT
26
2017
OCT
26
2017
OCT
25
2017
OCT
25
2017
OCT
25
2017
OCT
25
2017
OCT
24
2017
OCT
24
2017
OCT
23
2017
OCT
23
2017
OCT
23
2017
OCT
23
2017
OCT
19
2017
OCT
19
2017
A new study found that Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and no early grade 3 radiation-related toxicities.
SEP
11
2017
SEP
11
2017
Proton Therapy: The New Weapon to Fight Cancer
by ASHLEY HAY, BSN, RN
AUG
03
2017
AUG
03
2017
Five-year results of a single-institution study show that proton beam radiotherapy given concurrently with chemotherapy offers promising clinical outcomes with good toxicity results compared with historical data.
MAR
21
2017
MAR
21
2017
The use of reirradiation with intensity-modulated proton therapy yielded strong overall survival with limited toxicity in patients with thoracic tumors, potentially offering a new option in this patient population.
MAR
15
2017
MAR
15
2017
In this article we discuss the specifics of refining current strategies for radiation delivery, as well as new and up-and-coming heavy particle techniques and radiotherapeutics.
JUN
2017
JUN
2017
From Particle Physics to Medical Applications
by Manjit Dosanjh
CERN is the world’s largest particle physics research laboratory. Since it was established in 1954, it has made an outstanding contribution to our understanding of the fundamental particles and their interactions, and also to the technologies needed to analyse their properties and behaviour. The experimental challenges have pushed the performance of particle accelerators and detectors to the limits of our technical capabilities, and these groundbreaking technologies can also have a significant impact in applications beyond particle physics. In particular, the detectors developed for particle physics have led to improved techniques for medical imaging, while accelerator technologies lie at the heart of the irradiation methods that are widely used for treating cancer.
Indeed, many important diagnostic and therapeutic techniques used by healthcare professionals are based either on basic physics principles or the technologies developed to carry out physics research. Ever since the discovery of x-rays by Roentgen in 1895, physics has been instrumental in the development of technologies in the biomedical domain, including the use of ionizing radiation for medical imaging and therapy. Some key examples that are explored in detail in this book include scanners based on positron emission tomography, as well as radiation therapy for cancer treatment. Even the collaborative model of particle physics is proving to be effective in catalysing multidisciplinary research for medical applications, ensuring that pioneering physics research is exploited for the benefit of all.
JAN
2017
JAN
2017
Proton Beam Therapy
by Harald Paganetti
Cancer therapy is a multi-modality approach including surgery, systemic or targeted chemotherapy, radiation (external beam or radionuclide), and immunotherapy. Radiation is typically administered using external beam photon therapy. Proton therapy has been around for more than 60 years but was restricted to research laboratories until the 1990s. Since then clinical proton therapy has been growing rapidly with currently more than 50 facilities worldwide. The interest in proton therapy stems from the physical properties of protons allowing for advanced dose sculpting around the target and sparing of healthy tissue. This review first evaluates the basics of proton therapy physics and technology and then outlines some of the current physical, biological, and clinical challenges. Solving these will ultimately determine whether proton therapy will continue on its path to becoming mainstream.